Company / Operating Income
Compass Therapeutics, Inc. Operating Income History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$56.6M
FY2024
5-year range
-$81.9M / -$27.8M
FY2020-FY2024
Trend
-12.4%
vs FY2023
Sector context
#74 of 204
Health Care
What the data says
At -$57M, Compass Therapeutics, Inc.'s operating income ranks #74 of 204 in the Health Care sector. Operating Income has fluctuated over the past 7 years, ranging from -$82M in FY2021 to -$32,759 in FY2018.
Based on SEC 10-K filings.
-$57M in FY2024.
Declined from -$42M to -$57M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#74 of 204 in Health CareTop 36% of 204This company -$56.6M Sector average $107.7M
▼
-152.6% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 12.4% year-over-year.
- Ranks #74 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$56.6M | -12.4% |
| FY2023 | -$50.4M | -20.9% |
| FY2022 | -$41.7M | +49.1% |
| FY2021 | -$81.9M | -194.4% |
| FY2020 | -$27.8M | +18.3% |
| FY2019 | -$34.1M | -103847.0% |
| FY2018 | -$32.8K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026